Search research articles
Contact Us
Filters
Showing results (121-130 of 133) with videos related to
Page
of 14
Sort By:
Tissue Antigens
|
April 25, 2000
Routine HLA-B genotyping with PCR-sequence-specific oligonucleotides (PCR-SSO) detects eight new alleles: B*0807, B*0809, B*1551, B*3529, B*3532, B*4025, B*5304 and B*5508
C T Kennedy, R Dodd, T Le, et al.
Blood Advances
|
May 18, 2022
Allelic complexity of KMT2A partial tandem duplications in acute myeloid leukemia and myelodysplastic syndromes
Harrison K Tsai, Christopher J Gibson, H Moses Murdock, et al.
Blood Advances
|
February 2, 2026
CPX-351 Selectively Benefits Patients with AML and Myelodysplasia-Related Mutations in the Pivotal Randomized Trial
Shai Shimony, H Moses Murdock, Julia H Keating, et al.
Blood Advances
|
January 10, 2024
Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML
Jacqueline S Garcia, Haesook T Kim, H Moses Murdock, et al.
Blood
|
March 14, 2022
Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML
H Moses Murdock, Haesook T Kim, Nathan Denlinger, et al.
Blood Cancer Journal
|
September 23, 2022
Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group's clinical trial E3999
Franck Rapaport, Kenneth Seier, Yaseswini Neelamraju, et al.
Blood Advances
|
October 6, 2021
Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active
Jacqueline S Garcia, Haesook T Kim, H Moses Murdock, et al.
Blood Cancer Journal
|
July 5, 2023
Correction: Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group's clinical trial E3999
Franck Rapaport, Kenneth Seier, Yaseswini Neelamraju, et al.
Blood Advances
|
December 5, 2025
Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor risk MDS/AML
Jacqueline S Garcia, Haesook T Kim, H Moses Murdock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2021
Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation
Christopher J Gibson, Haesook T Kim, Lin Zhao, et al.
Page
of 14
Search research articles
Search
Showing results (121-130 of 133) with videos related to
Sort By:
Page
of 14
Tissue Antigens
|
April 25, 2000
Routine HLA-B genotyping with PCR-sequence-specific oligonucleotides (PCR-SSO) detects eight new alleles: B*0807, B*0809, B*1551, B*3529, B*3532, B*4025, B*5304 and B*5508
C T Kennedy, R Dodd, T Le, et al.
Blood Advances
|
May 18, 2022
Allelic complexity of KMT2A partial tandem duplications in acute myeloid leukemia and myelodysplastic syndromes
Harrison K Tsai, Christopher J Gibson, H Moses Murdock, et al.
Blood Advances
|
February 2, 2026
CPX-351 Selectively Benefits Patients with AML and Myelodysplasia-Related Mutations in the Pivotal Randomized Trial
Shai Shimony, H Moses Murdock, Julia H Keating, et al.
Blood Advances
|
January 10, 2024
Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML
Jacqueline S Garcia, Haesook T Kim, H Moses Murdock, et al.
Blood
|
March 14, 2022
Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML
H Moses Murdock, Haesook T Kim, Nathan Denlinger, et al.
Blood Cancer Journal
|
September 23, 2022
Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group's clinical trial E3999
Franck Rapaport, Kenneth Seier, Yaseswini Neelamraju, et al.
Blood Advances
|
October 6, 2021
Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active
Jacqueline S Garcia, Haesook T Kim, H Moses Murdock, et al.
Blood Cancer Journal
|
July 5, 2023
Correction: Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group's clinical trial E3999
Franck Rapaport, Kenneth Seier, Yaseswini Neelamraju, et al.
Blood Advances
|
December 5, 2025
Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor risk MDS/AML
Jacqueline S Garcia, Haesook T Kim, H Moses Murdock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2021
Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation
Christopher J Gibson, Haesook T Kim, Lin Zhao, et al.
Page
of 14